𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻

Asst Prof| Medical Oncologist| Medical Educator| @annualsdui SDUI 2017-2020|🇸🇩🇮🇪

[𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻 @YasarHammor]

Some call us Arabs, some call us Africans, and some call us Afro-arab... Being Sudanese is not about ethnicity, it's all about the values that we embrace, love we share, ethics and values embroided to our souls.
#SudanProtests
#SudanUprising
#السودان

[ESOncology @ESOncology]

📣 Applications are open for the 2nd cohort of the Certificate of Advanced Studies in Thoracic Malignancies (CAS-TM)!

Developed in joint collaboration between the ESO and @unifr, this prestigious postgraduate programme focuses on advancing both the clinical and scientific aspects of quality care in lung cancer and thoracic malignancies management.

📌 Upon successful completion and final examination, participants will receive an official academic certificate from the University of Fribourg granting 14 ECTS credits (equalling 420 hours of study) and a diploma supplement.

Structure: 4 online modules + 3 in person seminars
Start date next cohort: 17 March 2027

Chairs: Alessandra Curioni Fontecedro, CH; Christian Rolfo, MD, PhD, MBA,Dr.hc, US; Jarushka Naidoo, IE

Application deadline: 30 September 2026
Read more: https://t.co/Z69ECN1Jp9

[𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻 @YasarHammor]

The ethical justification for randomising patients with low PD-L1 to pembro monotherapy is highly questionable. These patients would typically receive chemo-immunotherapy which is the current standard of care for low PD-L1 advanced NSCLC without driver alterations.
Instead the trial offered pembro alone in the control arm a regimen known to be inferior to chemo-immuno in the low PD-L1 population.
Patients often enroll in phase 3 trials hoping for access to the experimental arm (here, sac-TMT + pembro), yet they risk being assigned to a suboptimal control that does not reflect real-world SOC.
As a result, even with the impressive PFS benefit (HR 0.35), the trial’s clinical implications are limited.
A flawed comparator makes it difficult to determine whether sac-TMT truly adds value over what patients should already be receiving today. The selection of the control arm is not just questionable it undermines the relevance of the entire study.

[The Lancet @TheLancet]

Presented at #ASCO26—OptiTROP-Lung05 phase 3 interim analysis.

The findings suggest first-line treatment with sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly prolonged PFS vs pembrolizumab alone in patients with PD-L1-positive advanced NSCLC without targetable genomic alterations.

Read more: https://t.co/I93eZXQbO6

[Christian Rolfo @ChristianRolfo]

Very exciting news for our patients with EGFR Exon 20 insertion Mut, game changer! Great to have options!

Very proud to see our own Dr Regan Memmott being a co-author of this important publication at @NEJM and representing @OhioStateMedOnc
@OSUCCC_James
#ASCO26
@EGFRSummit

[𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻 @YasarHammor]

"AI will not replace oncologists. But oncologists who use AI will replace those who don't."

It hallucinated a clinical trial that does not exist, confidently cited a paper with the wrong author, and gave a management plan that was three guidelines out of date.
So here is my honest view as someone who has published on AI in medical education📔 & medical oncology🦀 and uses it daily.
✅ What AI does well:
▪️ Summarising large volumes of literature fast
▪️ Generating teaching scenarios and case vignettes ▪️ Supporting self-directed learning for trainees
▪️ Drafting and structuring educational content

❌ What AI cannot replace:
▪️ Clinical reasoning at the bedside
▪️ The judgement that comes from sitting with a patient at the hardest moment of their life
▪️ The educator who knows when a trainee is struggling — not just academically, but humanly
▪️ Accountability for a wrong answer
The future of oncology education is not AI or the clinician-educator.

It is the clinician-educator who knows how to use AI well and when not to trust it.
We need to teach this. Now. Before the trainees we are forming learn it the hard way.
#MedEd #ArtificialIntelligence #MedicalEducation #Oncology #ClinicalTraining #MedTwitter

[𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻 @YasarHammor]

Honored to receive the 2026 @SpringerNature Editor of Distinction Award (Author Service Award) for my work with BMC Medical Education 💪
Recognized in the top 20% globally for delivering an efficient and fair peer-review experience for authors. #MedEd #AcademicTwitter

[Hidehito HORINOUCHI @HHorinouchi]

🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1
🆙 @JCO_ASCO
☑Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC
🎙Dr. Lyudmila Bazhenova @HHorinouchi
#LCSM @OncoAlert @Larvol
https://t.co/k4lOuFfjrl

[FC Barcelona @fcbarcelona_fra]

Bonne fête de l'#EidAlAdha à tous nos supporteurs musulmans ! ✨

[𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻 @YasarHammor]

Glad to share my latest publication in @IMJ_IRL :

"Pathological Response and Toxicity of Neoadjuvant Immunotherapy in Advanced Melanoma"

Neoadjuvant immunotherapy is reshaping how we think about advanced melanoma shifting the treatment sequence upstream of surgery and opening a window to assess biological response before the blade. This work examines pathological response rates and toxicity profiles in this setting, with a focus on what the data means for real-world clinical decision-making.

The findings speak to a field in motion. Response-adapted strategies, surgical de-escalation in deep responders, and the weight of irAE burden on treatment delivery are no longer theoretical concerns they are the lived questions of every melanoma multidisciplinary team.
@haileykcarroll @svuh
🔗 https://t.co/ckO9evP2R0

#Melanoma #MedicalOncology #Immunotherapy #NeoadjuvantTherapy #CancerResearch

[𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻 @YasarHammor]

@travisakers Sudan 🇸🇩

[Dr Sinead Toomey @sinead_toomey]

Fully funded PhD opportunity available in our lab, investigating exhaled breath condensate to detect and monitor lung cancer. Apply using link below
https://t.co/fCUScRGjzh

[UN Human Rights Council Investigative Bodies @uninvhrc]

#SUDAN | "No durable solution can be achieved through military means alone," the @UN & @achpr_cadhp Fact-Finding Missions said in a joint statement today.

Learn more ➡️ https://t.co/6iFl4EUPyd

[𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻 @YasarHammor]

@aalbeirutty

[SDUI @AnnualSdui]

Sudanese medical organizations across the diaspora have issued a joint international appeal calling for the protection of healthcare workers and reaffirmation of MedicalNeutrality in Sudan.

Healthcare workers must never be treated as combatants, intelligence assets, or political actors. Hospitals, ambulances, and medical personnel are protected under international humanitarian law.

We call on international organizations and human rights bodies to condemn attacks, threats, and intimidation against healthcare workers and to support independent and safe medical practice in Sudan.

Sudanese doctors continue to serve civilians under extraordinarily difficult and dangerous conditions with professionalism, humanity, and dignity.

[Diego A. Díaz-García @diegoadiazg]

🫁 Fixed-dose vs weight-based pembrolizumab in NSCLC.

Real-world data showed comparable OS and irAE rates between fixed-dose (200 mg Q3W) and weight-based dosing (2 mg/kg Q3W).
Potential cost-saving strategy for underweight patients and resource-limited settings without compromising outcomes.

📖 JCO Oncology Practice
DOI 👉🏻 https://t.co/AQEQmUUtSV

#CánCare #nsclc #lcsm #immunotherapy

[Uğur Özkerim @UOzkerim]

PACIFIC remains one of the hardest standards to beat in unresectable stage III #NSCLC.

Adding concurrent nivolumab ± ipilimumab to CCRT failed to improve PFS or OS versus standard durvalumab consolidation — while increasing pneumonitis.

More IO ≠ better IO. 🫁

@OncoAlert @MedicalwatchHQ @MedwatchKate @OncoReporte @Lung_Cancers @LungCancerEu @LungCancerRx @OncBrothers @Larvol

[Sociedad Mexicana de Oncología, A.C. @SMEOMX]

📋 Programa disponible | Sesión Académica Virtual SMeO

Especialistas revisarán los retos actuales en el manejo multidisciplinario del #Melanoma, incluyendo abordaje quirúrgico, tratamiento sistémico y discusión clínica.

📅 19 mayo 2026
🕗 20:00 hrs
🔗 https://t.co/jIQ0b3k3Ww

#OncologíaMX #SMeO #EducaciónMédica

[The Immunobuddies Podcast @immunobuddies]

There’s a quiet shift happening

PPIs used to be routine alongside steroids

Now clinicians are asking why

If there’s no clear benefit and real downside risk should we be using them at all?

🎧 Listen: https://t.co/UDswebDMCu ‌

@RickyFrazer1 @AOlssonBrown
#ImmunoOncology #MedicationSafety #Healthcare

[Dr Husam El-mugamar @DrElmugamar]

No impunity! #sudan @Sarajalilo @SUWRA1 @YasarHammor @WailAbdu @P4HR

[Sudan's Doctors for Human Rights @sudan_doctors]

Sudan’s Doctors for Human Rights strongly condemns the violent assault on several Sudanese women and men who were peacefully protesting in Oxford, carried out by a group supporting the war in Sudan.#Sudan @Sarajalilo @YasarHammor @WailAbdu

[𝓨𝓪𝓼𝓪𝓻 𝓗𝓪𝓶𝓶𝓸𝓻 @YasarHammor]

𝗖𝗛𝗔𝗠𝗣𝗜𝗢𝗡𝗦 🏆 It's not just a League. It's history ❤️